Akriderm, 0.05% ointment 15 g

Pharmacodynamics

Acriderm® is a glucocorticosteroid for external use. It has anti-inflammatory, anti-allergic, anti-exudative, vasoconstrictor, antipruritic and antiproliferative effects. It inhibits leukocyte accumulation, release of lysosomal enzymes and proinflammatory mediators in the inflammation focus, inhibits phagocytosis, decreases vascular and tissue permeability and prevents inflammatory edema formation.

When applied to the skin surface, the drug performs fast and strong action in the area of inflammation, reducing the severity of objective symptoms (erythema, edema, lichenification) and subjective sensations (itching, irritation, pain).

Pharmacokinetics

Transdermal absorption of the active substance into blood is very low when the drug is applied topically in therapeutic doses. The use of occlusive dressings, inflammation and skin conditions increase transdermal absorption of betamethasone, which may increase the risk of systemic side effects.

Indications

Skin diseases amenable to glucocorticosteroid therapy:

atopic dermatitis;
allergic contact dermatitis;
eczema (various forms);
contact dermatitis (including occupational) and other non-allergic dermatitis (including solar and radiation dermatitis);
reactions to insect bites;
psoriasis;
bullous dermatoses;
discoid lupus erythematosus;
lichen planus;
exudative multimorphic erythema;
skin itching of various etiologies.

Pharmacological effect

Pharmacodynamics

Akriderm® is a glucocorticosteroid for external use. It has anti-inflammatory, antiallergic, antiexudative, vasoconstrictive, antipruritic and antiproliferative effects. Inhibits the accumulation of leukocytes, the release of lysosomal enzymes and pro-inflammatory mediators at the site of inflammation, inhibits phagocytosis, reduces vascular tissue permeability, and prevents the formation of inflammatory edema.

When applied to the surface of the skin, the drug has a quick and strong effect at the site of inflammation, reducing the severity of objective symptoms (erythema, swelling, lichenification) and subjective sensations (itching, irritation, pain).

Pharmacokinetics

When the drug is applied cutaneously in therapeutic doses, transdermal absorption of the active substance into the blood is very insignificant. The use of occlusive dressings, inflammation and skin diseases increase the transdermal absorption of betamethasone, which may lead to an increased risk of systemic side effects.

Special instructions

If there is no effect of treatment within two weeks, it is recommended to consult your doctor for a possible clarification of the diagnosis. If irritation or hypersensitivity reaction is observed when using the drug, treatment should be stopped and consult your doctor. For secondary fungal or bacterial infections, appropriate medications must be used. If there is no immediate positive effect, the use of Akriderm should be discontinued until all signs of infection are eliminated.

Long-term use of the drug on the skin of the face is not recommended. Akriderm should not be used in the eye area, because… in this case, the development of cataracts, glaucoma, fungal infection and exacerbation of herpetic infection is possible.

Use in pediatrics

Children may be more susceptible to the use of topical corticosteroids that cause hypothalamic-pituitary-adrenal (HPA) axis suppression than older patients due to increased drug absorption associated with their larger surface area to body weight ratio. The following side effects were observed in children taking local corticosteroids: suppression of the HPA system function, Cushing’s syndrome, linear growth retardation, delayed weight gain, increased intracranial pressure.

Symptoms of adrenal suppression in children include decreased plasma cortisol levels and lack of response to ACTH stimulation. Increased intracranial pressure is manifested by bulging of the fontanel, headache, and bilateral papilledema.

Active ingredient

Betamethasone

Composition

100 g ointment contains:

active substance:

betamethasone dipropionate in terms of 100% substance – 0.064 g, which is equivalent to 0.05 g of betamethasone;

excipients:

propyl parahydroxybenzoate – 0.05 g,

liquid paraffin (vaseline oil) – 4 g,

isopropyl myristate – 1 g,

Vaseline – up to 100 g.

Pregnancy

The safety of topical use of glucocorticosteroids in pregnant women has not been established; the prescription of drugs in this group during pregnancy is justified only if the potential benefit to the mother outweighs the possible risk to the fetus.

Contraindications

Hypersensitivity to betamethasone or other components of the drug.

Side Effects

As a rule, it is of a weakly expressed nature.

When glucocorticosteroids are used externally, the following may be observed: skin itching, burning, irritation, dry skin, folliculitis, hypertrichosis, stretch marks, acne-like rashes (“steroid” acne), hypopigmentation, perioral dermatitis, allergic contact dermatitis.

With long-term use, as well as the use of occlusive dressings, skin maceration, secondary infection, skin atrophy, local hirsutism, telangiectasia, prickly heat, purpura. When applied to large surfaces of the body, mainly in children, systemic side effects of glucocorticosteroids may occur (hyperglycemia, glycosuria, reversible inhibition of adrenal function, manifestation of Itsenko-Cushing syndrome).

If adverse reactions occur that are not described in the instructions, you should consult a doctor.

Interaction

There are no clinically significant interactions with other drugs.

Overdose

Acute overdose is unlikely, however, with excessive or prolonged use of the drug, chronic overdose is possible, accompanied by signs of hypercortisolism: hyperglycemia, glycosuria, reversible inhibition of adrenal function, manifestation of Itsenko-Cushing syndrome.

Treatment: gradual withdrawal of the drug and, if necessary, symptomatic treatment are recommended.

Storage conditions

The drug should be stored out of the reach of children at a temperature of 15 to 25°C.

Shelf life

2 years.

Manufacturer

Akrikhin JSC, Russia